CINECA IRIS Institutional Research Information System

VIGATO, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.293
AS - Asia 879
EU - Europa 659
SA - Sud America 104
Continente sconosciuto - Info sul continente non disponibili 51
AF - Africa 15
OC - Oceania 4
Totale 3.005
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.256
IT - Italia 385
SG - Singapore 375
CN - Cina 170
BR - Brasile 78
VN - Vietnam 76
IN - India 66
KR - Corea 61
IE - Irlanda 49
DE - Germania 38
FR - Francia 38
GB - Regno Unito 38
JP - Giappone 35
HK - Hong Kong 23
BD - Bangladesh 20
CA - Canada 19
NL - Olanda 17
PT - Portogallo 11
SE - Svezia 11
AR - Argentina 10
PL - Polonia 9
CZ - Repubblica Ceca 8
IQ - Iraq 8
MX - Messico 8
PK - Pakistan 8
FI - Finlandia 7
BE - Belgio 6
CL - Cile 6
ID - Indonesia 6
UA - Ucraina 6
AT - Austria 5
IR - Iran 5
AU - Australia 4
DK - Danimarca 4
HU - Ungheria 4
NG - Nigeria 4
SK - Slovacchia (Repubblica Slovacca) 4
ES - Italia 3
ET - Etiopia 3
GE - Georgia 3
JM - Giamaica 3
LT - Lituania 3
UZ - Uzbekistan 3
ZA - Sudafrica 3
BO - Bolivia 2
CH - Svizzera 2
DO - Repubblica Dominicana 2
MA - Marocco 2
MY - Malesia 2
OM - Oman 2
PE - Perù 2
PH - Filippine 2
PR - Porto Rico 2
PY - Paraguay 2
SA - Arabia Saudita 2
TH - Thailandia 2
TN - Tunisia 2
TR - Turchia 2
TW - Taiwan 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BH - Bahrain 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
DZ - Algeria 1
EC - Ecuador 1
EE - Estonia 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
IL - Israele 1
LB - Libano 1
LV - Lettonia 1
NO - Norvegia 1
NP - Nepal 1
RO - Romania 1
RS - Serbia 1
RU - Federazione Russa 1
SI - Slovenia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 2.954
Salva come PNG Salva come JPEG
Città #
Singapore 211
San Jose 206
Ashburn 164
Los Angeles 126
Turin 94
Santa Clara 90
Seoul 59
Milan 57
Hefei 53
Dublin 50
Beijing 47
Rome 44
Chandler 32
Tokyo 31
Ho Chi Minh City 30
New York 27
Hanoi 22
Bengaluru 21
Columbus 19
Lauterbourg 19
The Dalles 19
Brooklyn 11
Buffalo 11
Lisbon 11
London 11
Nyköping 11
Boardman 10
Dallas 10
Hong Kong 10
São Paulo 9
Bologna 8
Lucknow 8
Naples 8
Nuremberg 8
Orem 8
Council Bluffs 7
Hangzhou 7
Pune 7
Redondo Beach 7
Atlanta 6
Bradford 6
Leeds 6
Munich 6
Rivoli 6
Seattle 6
Washington 6
Boston 5
Chicago 5
Düsseldorf 5
Florence 5
Lahore 5
Medford 5
New Delhi 5
Toronto 5
Abuja 4
Amsterdam 4
Bad Rappenau 4
Copenhagen 4
Frankfurt am Main 4
Krakow 4
Luni 4
Mexico City 4
Montreal 4
Opatovice nad Labem 4
Princeton 4
Warsaw 4
Addis Ababa 3
Alessandria 3
Baghdad 3
Barcelona 3
Bratislava 3
Budapest 3
Calci 3
Campinas 3
Charlotte 3
Cincinnati 3
Curitiba 3
Gainesville 3
Garbagnate Milanese 3
Genoa 3
Haiphong 3
Helsinki 3
Jacksonville 3
Johannesburg 3
Juiz de Fora 3
Mechelen 3
Medan 3
Modena 3
Morena 3
Paris 3
Rio de Janeiro 3
Santiago 3
Scarborough 3
Tashkent 3
Vienna 3
Wasquehal 3
Albignasego 2
Antioch 2
Bari 2
Belo Horizonte 2
Totale 1.811
Salva come PNG Salva come JPEG
Nome #
New inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3) based on benzoisoxazole scaffold and their potential application in cancer 198
New Hydroxybenzoazole Inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3): Disclosure of SAR Investigation to Target Prostate Cancer 190
AI-powered discovery and structure-based optimization of new 7-hydroxycoumarine-based AKR1C3 inhibitors able to reverse chemoresistance in aggressive and rare tumors 184
Design of new human Dihydroorotate Dehydrogenase inhibitors: amide bioisosterism in MEDS433 optimization 179
Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer 158
The (bio)chemical beaUty: La bellezza del faRmaCo attraverso la ReAltà Virtuale (URCA!) 131
AI Based Discovery of a New AKR1C3 Inhibitor for Anticancer Applications 129
Enhancement of the metabolic stability in 2-hydroxypyrazolo[1,5-a]pyridine scaffold-based inhibitors of human dihydroorotate dehydrogenase (hDHODH) 126
A new generation of AKR1C3 inhibitors on the horizon: the 3- hydroxybenzazole approach to target prostate cancer 121
Improvement of metabolic weakness of new human Dihydroorotate Dehydrogenase inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold 117
Phenothiazines as anti-cancer agents: SAR overview and synthetic strategies 113
Application of an in house bioisosteric approach to the design of innovative inhibitors of aldo-keto reductase 1C3 (AKR1C3) 112
HYDROXYLATED HETEROCYCLES AS BIOISOSTERES OF THE CARBOXYLIC FUNCTION: DESIGN OF NEW AKR1C3 INHIBITORS ACTIVE IN PROSTATE CANCER 110
Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2- hydroxypyrazolo[1,5-a]pyridine scaffold: from academy to clinic 110
Important steps into drug development of MEDS433, a potent human dihydroorotate dehydrogenase inhibitor based on the 2-hydroxypyrazolo[1,5-a]pyridine scaffold 108
Overcoming of metabolic issues in 2-hydroxypyrazolo[1,5-a]pyridine scaffold-based inhibitors of human dihydroorotate dehydrogenase: the story of MEDS700 102
Important Steps into Drug Development of MEDS433, a Potent Human Dihydroorotate Dehydrogenase Inhibitor based on the 2-hydroxypyrazolo[1,5-a] Pyridine Scaffold 102
Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2-hydroxypyrazolo[1,5-a]pyridine scaffold: from academy to clinic 101
Targeting myeloid leukemias using human Dihydroorotate Dehydrogenase inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold: overcoming of metabolic issues 97
Improvement of Metabolic Weakness of New Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold to Target Myeloid Leukemias 90
Targeting Myeloid Leukemias Using human Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: Overcoming of Metabolic Issues 88
Optimization of MEDS433 synthesis: scale-up for preclinical evaluation studies 86
Application of an in house bioisosteric approach to the design of innovative inhibitors of aldo-keto reductase 1C3 (AKR1C3) 84
Improvement of Metabolic Weakness of New Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold to Target Myeloid Leukemias 75
Optimization of MEDS433 synthesis: scale-up for preclinical evaluation studies 67
Targeting dihydroorotate dehydrogenase (hDHODH) beyond the barrier: discovery of MEDS700 as blood-brain barrier permeable hDHODH inhibitor 20
Inhibition of Enzymes Involved in the Induction of Apoptosis and Differentiation as well as Drug-Resistance in Myeloid Leukemias 7
Totale 3.005
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.631
article - articoli 0
book - libri 0
conference - conferenze 8.972
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.603
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202244 0 0 0 0 0 0 0 0 0 10 21 13
2022/2023252 22 18 12 9 10 86 29 13 16 4 15 18
2023/2024345 30 25 14 14 12 26 133 13 4 22 23 29
2024/2025699 31 41 61 55 110 69 19 27 89 28 66 103
2025/20261.343 178 92 64 150 105 37 216 33 114 142 92 120
2026/2027322 165 157 0 0 0 0 0 0 0 0 0 0
Totale 3.005